聚乙二醇化多柔比星脂质体在乳腺癌中的应用进展  

Application Progress of Pegylated Liposome Doxorubicin in Breast Cancer

作　　者：丁风娇 赵默 丁波泥[1] DING Fengjiao;ZHAO Mo;DING Boni(Department of Breast and Thyroid Surgery,the Third Xiangya Hospital Affiliated to Central South University,Changsha 410013,China;Department of Clinical Medicine,Hainan Medical College,Haikou 571199,China)

机构地区：[1]中南大学湘雅三医院乳甲外科,长沙410013 [2]海南医学院临床医学系,海口571199

出　　处：《医学综述》2025年第2期157-162,共6页Medical Recapitulate

基　　金：新锐肿瘤支持治疗课题研究项目(cphcf-2022-079);吴阶平医学基金会临床科研专项资助基金课题(320.6750.2023-18-18)。

摘　　要：蒽环类药物是乳腺癌化疗的常用药物,但较明显的不良反应限制了其临床使用。新型蒽环类药物聚乙二醇化多柔比星脂质体(PLD)具有特殊的结构,其用于治疗乳腺癌的效果与传统蒽环类药物相当,且不良反应发生率较低,主要不良反应为手足综合征和口腔黏膜炎,但一般不影响化疗进程。然而,目前PLD在乳腺癌辅助化疗和新辅助化疗中应用的循证医学证据尚不足,故仍主要推荐使用传统蒽环类药物。未来,期待开展更多有关PLD用于乳腺癌各期治疗的高质量临床试验,以为乳腺癌合理用药提供临床依据。Anthracyclines drugs are commonly used in chemotherapy of breast cancer,but their clinical use is limited by the obvious adverse reactions.The pegylated liposome doxorubicin(PLD),a new anthracycline drug,has a special structure.Its effect in the treatment of breast cancer is comparable to that of traditional anthracycline drugs,and the incidence of adverse reactions is low.The main adverse reactions are hand foot syndrome and oral mucositis,but generally do not affect the chemotherapy process.However,the evidence-based medical evidence for the application of PLD in adjuvant chemotherapy and neoadjuvant chemotherapy for breast cancer is still insufficient,so traditional anthracycline drugs are still mainly recommended.In the future,it is expected to carry out more high-quality clinical trials on the use of PLD in breast cancer treatment at all stages,so as to provide clinical basis for the rational drug use in breast cancer.

关 键 词：乳腺癌 聚乙二醇化多柔比星脂质体 化疗 

分 类 号：R737.9[医药卫生—肿瘤]